Feedback

How Does the TRIPS Agreement Affect India's Patent Laws and Access to Medicines?

The significance of intellectual property in global trade and commerce has necessitated robust international protection and enforcement mechanisms. The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) emerged to address these needs, setting out guidelines for the protection and enforcement of intellectual property rights. This paper explores the impact of the TRIPS Agreement on India's patent laws, particularly in the context of the Patents Act, 1970, and the implications for accessibility to affordable medicines.

INTRODUCTION

The TRIPS Agreement, which came into force on January 1, 1995, under the auspices of the World Trade Organization (WTO), aims to harmonize intellectual property rights across member nations. The Agreement promotes adequate protection of intellectual property rights while reducing trade impediments and ensuring that enforcement measures do not obstruct legitimate trade. Article 7 of the TRIPS Agreement emphasizes the promotion of technological innovation and the dissemination of technology to benefit both producers and users of technological knowledge in a manner conducive to social and economic welfare.

IMPACT OF THE TRIPS AGREEMENT IN LIGHT OF THE PATENTS ACT

The implementation of the TRIPS Agreement in India has had a mixed impact on innovation and accessibility to medicines. On the one hand, it has incentivized investment in research and development by ensuring protection for inventors. On the other hand, amendments to the Patents Act, 1970, to align with TRIPS standards have raised challenges for local manufacturers, especially in the pharmaceutical sector.

Key changes included the removal of provisions that previously facilitated the production of generic medicines and the narrowing of the scope for issuing compulsory licenses. These changes have made it easier to patent minor modifications of existing drugs, leading to higher drug prices and reduced accessibility.

The landmark case of Novartis A.G. v Union of India further restricted the interpretation of Section 3(d) of the Patents Act, making it harder for companies to manufacture modified versions of existing drugs.

TRIPS AGREEMENT AND PUBLIC HEALTH

During the COVID-19 pandemic, the TRIPS Agreement was spotlighted as India and South Africa proposed waiving certain TRIPS provisions to increase access to vaccines and drugs. The proposal faced opposition from pharmaceutical giants, highlighting the tension between rewarding innovation and ensuring public health.

COMMENTS

India's IP infrastructure needs enhancement through the establishment of IP courts and the inclusion of IP courses in legal education. Public awareness campaigns and government incentives for research and development are crucial. Balancing intellectual property protection with public interest remains a priority, requiring prudent legislative measures.

CONCLUSION